Yu YM, Jin GH, Zhong C, Qian H, Wang L, Zhan F. Exploring the role of interleukin-6 receptor blockade in epilepsy and associated neuropsychiatric conditions through a mendelian randomization study. World J Psychiatry 2024; 14(8): 1244-1253 [DOI: 10.5498/wjp.v14.i8.1244]
Corresponding Author of This Article
Feng Zhan, MMed, Associate Chief Physician, Department of Pediatrics, The First People's Hospital of Chuzhou, No. 369 Zuiweng West Road, Nanqiao District, Chuzhou 239001, Anhui Province, China. zf23260523@163.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Yan-Mei Yu, Gui-Hong Jin, Chong Zhong, Hao Qian, Feng Zhan, Department of Pediatrics, The First People's Hospital of Chuzhou, Chuzhou 239001, Anhui Province, China
Lei Wang, Department of Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, Zhejiang Province, China
Author contributions: Yu YM, Jin GH, Wang L and Zhan F drafted the initial manuscript, analyzed the data, and interpreted the results; Yu YM, Jin GH, Zhong C, Qian H, and Zhan F designed the study, analyzed the data, and critically revised the manuscript; All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Zhan, MMed, Associate Chief Physician, Department of Pediatrics, The First People's Hospital of Chuzhou, No. 369 Zuiweng West Road, Nanqiao District, Chuzhou 239001, Anhui Province, China. zf23260523@163.com
Received: June 13, 2024 Revised: July 5, 2024 Accepted: July 11, 2024 Published online: August 19, 2024 Processing time: 59 Days and 21.8 Hours
Core Tip
Core Tip: This study employed mendelian randomization to explore the potential neuroprotective role of interleukin (IL)-6 receptor blockade in epilepsy, highlighting how it may decrease the incidence of epilepsy by addressing neuro-inflammatory and possibly non-inflammatory pathways. While the results shown a modest reduction in epilepsy risk, they vary across epileptic subtypes and suggested complex interactions with neuropsychiatric conditions. The findings underscored the necessity for further comprehensive investigations to understand the multifaceted effects of IL-6 signaling on both epilepsy and related psychiatric disorders, potentially paving the way for innovative therapeutic strategies that encompass neurological and psychiatric care in epilepsy management.
